Calciphylaxis Global Market Report 2025

The calciphylaxis market size has grown rapidly in recent years. It will grow from $3.22 billion in 2024 to $3.55 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The growth during the historic period can be attributed to the rising prevalence of chronic kidney disease, growing awareness of rare diseases, increasing government support for rare disease research, favorable regulatory environments, and higher healthcare expenditure.

The calciphylaxis market size is expected to see strong growth in the next few years. It will grow to $5.13 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period is expected to be driven by the expanding global aging population, emerging therapeutic innovations, increased access to dialysis in developing regions, rising investment in rare disease drug development, and the growing incidence of end-stage renal disease. Key trends during this period include advancements in dialysis and renal care, the development of treatments for mineral and bone disorders, progress in personalized medicine, advancements in biotechnology, therapeutic innovations, and improvements in healthcare policy.

The increasing incidence of chronic kidney disease (CKD) is expected to drive the growth of the calciphylaxis market. CKD is a long-term condition where the kidneys gradually lose their ability to filter waste and excess fluids from the blood, which can lead to kidney failure over time. Contributing factors to the rise in CKD include an aging population, the increasing prevalence of diabetes and hypertension, unhealthy lifestyle habits, and insufficient early detection and management of kidney-related conditions. Calciphylaxis is a critical marker of severe vascular complications in CKD, highlighting the importance of early intervention and improved management of mineral imbalances to prevent tissue necrosis and associated health issues. For example, the Australian Institute of Health and Welfare reported in December 2024 that chronic kidney disease mortality rates rose gradually from 2021 to 2022, with an increase of 4.2% in 2021 and 6.2% in 2022, indicating a sharper rise in the latter year. This growing prevalence of CKD is fueling the demand for treatments in the calciphylaxis market.

The rising prevalence of obesity is also expected to contribute to the growth of the calciphylaxis market. Obesity, which is characterized by excessive body fat accumulation, increases the risk of a range of health problems, including heart disease, diabetes, and hypertension. Factors contributing to the rise in obesity include sedentary lifestyles, high-calorie diets, genetic predisposition, and limited access to healthy food options. The risk of calciphylaxis increases with obesity due to metabolic dysfunction, chronic inflammation, and vascular calcification, which exacerbate calcium-phosphate imbalance and endothelial damage, particularly in individuals with chronic kidney disease. For instance, in September 2023, the Centers for Disease Control and Prevention (CDC) reported that, by 2022, 22 states in the United States had an adult obesity rate of 35% or higher, up from 19 states in 2021. This growing obesity prevalence is contributing to the expansion of the calciphylaxis market.

Major companies in the calciphylaxis market are increasingly focusing on developing innovative therapies, such as enzyme replacement therapy, to improve treatment outcomes and alleviate the severity of the condition. Enzyme replacement therapy (ERT) is a treatment that involves replacing a missing or deficient enzyme in the body. It is typically used to treat rare genetic disorders where the body cannot produce a specific enzyme necessary for normal cell function. For example, Inozyme Pharma Inc., a U.S.-based biopharmaceutical company, announced in October 2024 that its Phase 1 SEAPORT 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients yielded positive interim results. The data suggests that INZ-701 has the potential to restore enzyme activity critical for preventing abnormal mineralization, a key factor in severe rare diseases. INZ-701 targets ENPP1 and ABCC6 deficiencies, which are associated with pathological calcium buildup in blood vessels and tissues.

Major players in the calciphylaxis market are Baxter International Inc., Opko Health Inc., and Hope Pharmaceuticals Ltd.

North America was the largest region in the calciphylaxis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calciphylaxis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the calciphylaxis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Calciphylaxis is a rare and serious condition marked by the calcification of small blood vessels, resulting in skin necrosis and severe pain. It is studied to understand vascular calcification disorders and to develop targeted treatments aimed at improving wound healing and pain management in affected patients.

The main types of calciphylaxis include non-uremic calciphylaxis, ulcers and wounds, and debridement of wounds. Non-uremic calciphylaxis is a rare form that occurs in individuals without chronic kidney disease or dialysis. It involves abnormal calcium deposition in small blood vessels, leading to tissue damage, pain, and necrosis. Treatment options consist of drug therapy and hyperbaric calciphylaxis therapy, while diagnosis typically involves deep skin biopsies, blood tests, and imaging. Key end users for these treatments include hospitals, clinics, home care settings, and ambulatory centers.

The calciphylaxis market research report is one of a series of new reports that provides calciphylaxis market statistics, including calciphylaxis industry global market size, regional shares, competitors with a calciphylaxis market share, detailed calciphylaxis market segments, market trends and opportunities, and any further data you may need to thrive in the calciphylaxis industry. This calciphylaxis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The calciphylaxis market consists of revenues earned by entities by providing services such as chronic care management, nutritional counselling and patient management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The calciphylaxis market also includes sales of dialysis equipment, phosphate binders, vitamin k2 supplements, and wound care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.